Navigation Links
Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
Date:3/4/2013

Toronto, Canada (PRWEB) March 04, 2013

With the advent of direct acting antiviral agents for the Hepatitis C virus (HCV), there has been a concerted effort to offer broad testing services and capabilities to assist clients at every stage of drug development. From lead compound optimization and resistance profiling to Phase IV marketing studies, LabCorp and its specialty testing laboratories offer specialized, proprietary testing. In fact, LabCorp offers global central laboratory testing services to support HCV trials around the world.

In this webinar, a thorough overview of currently available HCV capabilities will be presented, including:

  •     Technical overview of HCV assay services, including resistance testing (mutation detection and replicon-based DAA susceptibility assays), viral load assays, genotype/subtype characterization and IL28B allele testing
  •     Appropriate timing and circumstances for each specific test
  •     How these assays can be used to support regulatory filings
  •     How LabCorp’s global reach can help clients conduct more cost-effective clinical trials

The presentation will also highlight ongoing and future HCV assay development activities, such as the implementation of next generation sequencing platforms and the expanded presence in China, Southeast Asia and Europe.

For more information about this event or to register, visit: http://xtks.in/xto575-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10472827.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CNIO researchers take part in the most comprehensive personalized medicine study performed to date
2. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
3. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
4. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
5. CIVCO to Present Comprehensive Motion Management Solutions at ASTRO 2012 Booth #10003
6. Dr. Ross Kaplan Offers New Comprehensive Acne Package Treatment for Acne and Acne Scarring
7. Taylor-Wharton CryoScience 'Partners For Life' Awards Liquid Nitrogen Freezer to Comprehensive Cancer Center at University of Alabama at Birmingham
8. Rigaku introduces the world’s most comprehensive biological SAXS system for the home lab
9. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Georgia (PRWEB) , ... December 05, 2016 , ... ... lignin-coated nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition claims ... There are also claims directed to combination with polymers, carbon fibers, graphene, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... to soon resume cervical and lumbar disc production, company President, Jake Lubinski will ... who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss the ...
(Date:12/5/2016)... - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) ... Monitoring Board (DSMB) for the Company,s Phase 3 ... has completed a second planned safety review and ... without any modifications. The DSMB reviewed available study ... concerns were identified. The DSMB will conduct additional ...
(Date:12/5/2016)... Research and Markets has announced the addition of Jain ... Companies" to their offering. ... , , ... development of sequencing technologies, and their applications. Current large and ... Various applications of sequencing are described including those for genetics, ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
Breaking Biology News(10 mins):